alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Exhibit 10.1

                               THIRD AMENDMENT TO
                     AMENDED AND RESTATED LICENSE AGREEMENT


     This Third Amendment to Amended and Restated License Agreement ("Third
Amendment") effective this 27th day of October, 2006 is between the University
of Chicago, an Illinois not-for-profit corporation ("UNIVERSITY"), having its
principal office at 5555 S. Woodlawn Avenue, Chicago, IL 60637 and Opexa
Therapeutics, Inc., a Texas corporation ("OPEXA") (formerly named
PharmaFrontiers Corp.) having its principal office at 2635 N. Crescent Ridge
Drive, The Woodlands, Texas 77381. Each hereunder may be referred to separately
as the ("Party"), or together as the ("Parties"). The Parties agree:

                                    RECITALS

A.   UNIVERSITY and PHARMAFRONTIERS have previously entered into an "Amended and
     Restated License Agreement" dated December 30, 2004 (the "License
     Agreement"); and

B.   UNIVERSITY and PHARMAFRONTIERS have previously entered into a "First
     Amendment to Amended and Restated License Agreement" dated October 31, 2005
     (the "First Amendment") and a "Second Amendment to Amended and Restated
     License Agreement" dated April 13, 2006 (the "Second Amendment"); and

C.   NOW, THEREFORE, in consideration of the mutual promises and obligations
     hereinafter set forth and for other good and valuable consideration, the
     receipt and sufficiency of which are hereby acknowledged, the Parties
     hereto agree as follows:

     1.0  Amendment of Paragraph 4.C.i of the License Agreement. The first
          sentence of Paragraph 4.C.i shall be deleted in its entirety and the
          following shall be inserted in lieu thereof:

               "PF shall pay to the University one and one half million
               ($1,500,000) US dollars upon the later of the occurrence of the
               First Financing or April 30, 2007."

          Further, in each instance in which the date "October 31, 2006" appears
          in Paragraph 4.C.i., as provided pursuant to the Second Amendment,
          such date shall be deleted and "April 30, 2007" shall be inserted in
          lieu thereof.

     2.0  No Other Amendments. This Third Amendment supersedes all prior
          amendments and shall be construed as part of the License Agreement.
          Except as specifically amended herein, the License Agreement shall
          remain in full force and effect.

     IN WITNESS WHEREOF, the Parties hereto have caused this Third Amendment to
be executed by their respective duly authorized officers or representatives and
signed below.


University of Chicago                        Opexa Therapeutics, Inc.


By:    /s/ Alan Thomas                       By:    /s/ David B. McWilliams
       -------------------------------              ----------------------------
Name:  Alan Thomas                           Name:  David B. McWilliams
Title: Director of Technology Transfer       Title: Chief Executive Officer
Date:  October 27, 2006                      Date:  October 27, 2006
EXHIBIT
32.2




CERTIFICATION
PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT


TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002





In
connection with the Quarterly Report of Juma Technology, Corp. (the "Company")
on Form 10-Q for the period ended March 31, 2009 as filed with the Securities
and Exchange Commission on the date hereof (the "Report"), I, Anthony Fernandez,
the Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C.
Section 1350, as adopted pursuant to Section. 906 of the Sarbanes-Oxley Act of
2002, that:





(1) The
Report fully complies with the requirements of section 13(a) or 15(d) of the
Securities Exchange Act of 1934; and





(2) The
information contained in the Report fairly presents, in all material respects,
the financial condition and results of operations of the Company.




/s/ Anthony
  FernandezAnthony
      Fernandez
                  Chief
      Financial Officer




May 13,
2009
**Exhibit 31.1**

 

**CERTIFICATIONS**

 

I, Patrick J. Dirk, certifythat:

 

1.             Ihave reviewed this report on Form 10-Q of TROY Group, Inc.;

 

2.             Basedon my knowledge, this report does not contain any untrue statement of amaterial fact or omit to state a material fact necessary to make the statementsmade, in light of the circumstances under which such statements were made, notmisleading with respect to the period covered by this report;

 

3.             Basedon my knowledge, the financial statements, and other financial informationincluded in this report, fairly present in all material respects the financialcondition, results of operations and cash flows of the registrant as of, andfor, the periods presented in this report;

 

4.             Theregistrant’s other certifying officer and I are responsible for establishingand maintaining disclosure controls and procedures (as defined in Exchange ActRules 13a-15(e) and 15d-15(e)) for the registrant and have:

 

(a)           designedsuch disclosure controls and procedures, or caused such disclosure controls andprocedures to be designed under our supervision, to ensure that materialinformation relating to the registrant, including its consolidatedsubsidiaries, is made known to us by others within those entities, particularlyduring the period in which this report is being prepared;

 

(b)           evaluatedthe effectiveness of the registrant’s disclosure controls and procedures andpresented in this report our conclusions about the effectiveness of thedisclosure controls and procedures, as of the end of the period covered by thisreport based on such evaluation; and

 

(c)           disclosedin this report any change in the registrant’s internal control over financialreporting that occurred during the registrant’s most recent fiscal quarter (theregistrant’s fourth fiscal quarter in the case of an annual report) that hasmaterially affected, or is reasonably likely to materially affect, theregistrant’s internal control over financial reporting; and

 

5.             Theregistrant’s other certifying officer and I have disclosed, based on our mostrecent evaluation, to the registrant’s auditors and the audit committee ofregistrant’s board of directors (or persons performing the equivalentfunctions):

 

(a)           allsignificant deficiencies and material weaknesses in the design or operation ofinternal control over financial reporting which are reasonably likely toadversely affect the registrant’s ability to record, process, summarize andreport financial information; and

 

(b)           anyfraud, whether or not material, that involves management or other employees whohave a significant role in the registrant’s internal control over financialreporting.

 

 
| Date:  October 15, 2004 | /s/Patrick  J. Dirk                    |   |
|-----------------------------------|----------------------------------------|--------|
|                              | Patrick J.  Dirk                       |
|                              | President  and Chief Executive Officer |

 

----
Exhibit 13.2

CERTIFICATION

(pursuant to 18 U.S.C. Section 1350, as adopted pursuant to

Section 906 of the Sarbanes-Oxley Act of 2002)

In connection with the Annual Report on Form 20-F for the fiscal year ended November 30, 2006 of Acergy S.A. (the Company) as filed with the U.S. Securities and Exchange Commission (the Commission) on the date
hereof (the Report) and pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, I, Stuart Jackson, Chief Financial Officer of the Company, certify, that:

(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.



|                     |  |                        
|-------------------- |  | -----------------------
|Date: April 18, 2007 |  | /s/ STUART JACKSON     
|                     |  | Stuart Jackson         
|                     |  | Chief Financial Officer
```

[Federal Register Volume 61, Number 2 (Wednesday, January 3, 1996)]
[Notices]
[Pages 166-167]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 96-00005]

-----------------------------------------------------------------------

FEDERAL RESERVE SYSTEM

J.G.D.B. y Cia. S. en C., et al.; Formations of; Acquisitions by; 
and Mergers of Bank Holding Companies

    The companies listed in this notice have applied for the Board's 
approval under section 3 of the Bank Holding Company Act (12 U.S.C. 
1842) and Sec.  225.14 of the Board's Regulation Y (12 CFR 225.14) to 
become a bank holding company or to acquire a bank or bank holding 
company. The factors that are considered in acting on the applications 
are set forth in section 3(c) of the Act (12 U.S.C. 1842(c)).
    Each application is available for immediate inspection at the 
Federal Reserve Bank indicated. Once the application has been accepted 
for processing, it will also be available for inspection at the offices 
of the Board of Governors. Interested persons may express their views 
in writing to the Reserve Bank or to the offices of the Board of 
Governors. Any comment on an application that requests a hearing must 
include a statement of why a written presentation would not suffice in 
lieu of a hearing, identifying specifically any questions of fact that 
are in dispute and summarizing the evidence that would be presented at 
a hearing.
    Unless otherwise noted, comments regarding each of these 
applications 

[[Page 167]]
must be received not later than January 31, 1996.
    A. Federal Reserve Bank of Atlanta (Zane R. Kelley, Vice President) 
104 Marietta Street, N.W., Atlanta, Georgia 30303:
    1. J.G.D.B. y Cia. S. en C. (formerly known as Jaime Gilinski y 
Cia. S. en C.), PBZ Ltda. y Cia. S. en C., and J.G.D.B. Limitada, all 
of Santa Fe de Bogota, Colombia, and Bloice Enterprises Corp., Colonel 
County Inc., Caprice Maritime Limited, Aileen International Co., Inc., 
Early Haven Investments Corp., Feldome Worldwide Corp., Foye 
Investments Inc., Garbay Isle Investments Inc., Jacklyn Finance Co. 
Ltd., and Swain Finance Co. Inc., all of Tortola, British Virgin 
Islands (collectively, Companies), and Bancol y Cia. S. en C. (Bancol), 
Santa Fe de Bogota, Colombia, to become bank holding companies and to 
retain, indirectly, all the voting securities of Eagle National Holding 
Company, and thereby retain 99.2 percent of the voting securities of 
Eagle National Bank of Miami, N.A., both of Miami, Florida. Companies, 
in the aggregate, own, directly or indirectly, all the voting 
securities of Bancol, which controls the power to vote 74.9 percent of 
the voting securities of Banco de Colombia, S.A., Santa Fe de Bogota, 
Colombia. In addition, Banco de Colombia, S.A., which indirctly owns 
all the voting securities of Eagle National Holding Company, Inc., 
proposes to acquire and directly own such shares.

    Board of Governors of the Federal Reserve System, December 27, 
1995.
Jennifer J. Johnson,
Deputy Secretary of the Board.
[FR Doc. 96-00005 Filed 1-2-96; 8:45 am]
BILLING CODE 6210-01-F
```
##### 



Exhibit 32(a) CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the filing of this quarterly report on Form 10-Q of Alpha Natural
Resources, Inc. (the Company) for the period ended March 31, 2005, with the Securities and
Exchange Commission on the date hereof (the Report), I, Michael J. Quillen, Chief Executive
Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section
906 of the Sarbanes-Oxley Act of 2002, that: 1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities
Exchange Act of 1934; and 2) The information contained in the Report fairly presents, in all material respects,
the financial condition and results of operations of the Company. The foregoing certification is being furnished solely pursuant to 18 U.S.C. § 1350 and is not
being filed as part of the Report or as a separate disclosure document. /s/ Michael J. Quillen
Michael J. QuillenPresident and Chief Executive Officer
(Principal Executive Officer) Date: May 16, 2005 A signed original of this written statement required by Section 906 has been provided to the
Company and will be retained by the Company and furnished to the Securities and Exchange Commission
or its staff upon request.
```

[Federal Register Volume 86, Number 109 (Wednesday, June 9, 2021)]
[Notices]
[Page 30611]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-12093]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Center for Advancing Translational Sciences; Notice of 
Closed Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended, notice is hereby given of the following meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Center for Advancing Translational 
Sciences Special Emphasis Panel; Multi-Disciplinary Machine-
assisted, Genomic Analysis and Clinical Approaches to Shortening the 
Rare Diseases Diagnostic Odyssey (UG3/UH3 Clinical Trial Optional).
    Date: July 14, 2021.
    Time: 9:00 a.m. to 4:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Center for Advancing Translational Sciences, 
National Institutes of Health, 6701 Democracy Boulevard, Room 1037, 
Bethesda, MD 20892 (Virtual Meeting).
    Contact Person: Nakia C. Brown, Ph.D., Scientific Review 
Officer, Office of Grants Management and Scientific Review, National 
Center for Advancing Translational Sciences, National Institutes of 
Health, 6701 Democracy Boulevard, Room 1037, Bethesda, MD 20892, 
301-827-4905, [email protected].

(Catalogue of Federal Domestic Assistance Program Nos. 93.859, 
Pharmacology, Physiology, and Biological Chemistry Research; 93.350, 
B--Cooperative Agreements; 93.859, Biomedical Research and Research 
Training, National Institutes of Health, HHS)

    Dated: June 4, 2021.
David W. Freeman,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2021-12093 Filed 6-8-21; 8:45 am]
BILLING CODE 4140-01-P
```
I 

118TH CONGRESS 

1ST SESSION H. R. 5640 

To designate the facility of the United States Postal Service located at 

12804 Chillicothe Road in Chesterland, Ohio, as the ‘‘Sgt. Wolfgang 

Kyle Weninger Post Office Building’’. 

IN THE HOUSE OF REPRESENTATIVES 

SEPTEMBER 21, 2023 

Mr. JOYCE of Ohio (for himself, Mr. LANDSMAN, Mr. WENSTRUP, Mrs. 

BEATTY, Mr. JORDAN, Mr. LATTA, Mr. JOHNSON of Ohio, Mr. MILLER

of Ohio, Mr. DAVIDSON, Ms. KAPTUR, Mr. TURNER, Ms. BROWN, Mr. 

BALDERSON, Mr. CAREY, and Mrs. SYKES) introduced the following bill; 

which was referred to the Committee on Oversight and Accountability 

A BILL 

To designate the facility of the United States Postal Service 

located at 12804 Chillicothe Road in Chesterland, Ohio, 

as the ‘‘Sgt. Wolfgang Kyle Weninger Post Office Building’’. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SGT. WOLFGANG KYLE WENINGER POST OF4 FICE BUILDING. 

5 (a) DESIGNATION.—The facility of the United States 

6 Postal Service located at 12804 Chillicothe Road in 


kjohnson on DSK7ZCZBW3PROD with $$_JOB
2 

•HR 5640 IH

1 Chesterland, Ohio, shall be known and designated as the 

2 ‘‘Sgt. Wolfgang Kyle Weninger Post Office Building’’. 

3 (b) REFERENCES.—Any reference in a law, map, reg4 ulation, document, paper, or other record of the United 

5 States to the facility referred to in subsection (a) shall 

6 be deemed to be a reference to the ‘‘Sgt. Wolfgang Kyle 

7 Weninger Post Office Building’’. 

Æ 


kjohnson on DSK7ZCZBW3PROD with $$_JOB
#### STATE of Missouri, Respondent, v. Michael SALES, Appellant.

No. 63424.

Missouri Court of Appeals, Eastern District, Southern Division.

June 30, 1995.

Motion for Rehearing and/or Transfer to Supreme Court Denied Aug. 14, 1995.

Eric E. Vickers, Vickers & Associates, St. Louis, for appellant.

Jeremiah W. (Jay) Nixon, Atty. Gen., Traci J. Sanders, Asst. Atty. Gen., Jefferson City, for respondent.

Before KAROHL, P.J., AHRENS and DOWD, JJ.

*ORDER*

PER CURIAM.

Defendant Michael Sales appeals the judgment of conviction on two counts of sale of a controlled substance in violation of § 195.211. Defendant was sentenced to thirty years imprisonment.

No jurisprudential purpose would be served by a written opinion. However, the parties have been furnished with a memorandum opinion for their information only, setting forth the facts and reasons for this order.

The judgment of the trial court is affirmed in accordance with Rule 30.25(b).
#### MONTFORT, INC., and Rodney Eugene Elliott, Petitioners, v. Dee Anna CARDENAS, Respondent.

No. 95-0254.

Supreme Court of Texas.

July 8, 1996.

Douglas R. Sanders, San Antonio, for Petitioners.

John A. Mead, Robert MeMurtry Hicks, San Antonio, for Respondent.

OPINION

PER CURIAM.

Dee Ann Cardenas was a passenger in a car driven by Richard Harris when the car collided with a tractor-trailer driven by Roney Elliott. Cardenas and Harris sued Elliott and his employer, Montfort, Incorporated, for injuries they sustained in the collision. Plaintiffs, both represented by attorney James Champion, demanded a jury trial and paid the requisite fee. Montfort also demanded a jury trial. Three weeks before the case was specially set for jury trial, Cardenas dismissed Champion as her attorney. Eight days later Champion formally withdrew from representing Cardenas, but he continued to represent Harris. When the case was called to trial, Cardenas appeared pro se, stated that she had been trying to obtain legal counsel without success, and asked for a continuance of the trial. The trial court denied Cardenas’ oral motion and proceeded to trial without a jury, the other parties’ having waived a jury. Cardenas did not object to trial before the bench. The court rendered judgment for Harris for $2,127.30 plus prejudgment interest, but denied Cardenas any recovery. Cardenas appealed, represented by Champion.

Cardenas argued that the trial court erred in denying her a jury trial, denying her motion for continuance, and excluding evidence of her damages. The court of appeals considered only the first issue, held by a divided vote that Cardenas did not waive trial by jury, and therefore reversed and remanded the case for a new trial. 894 S.W.2d 406. Montfort and Elliott petitioned for writ of error.

We find no error in the judgment of the court of appeals. However, we neither approve nor disapprove its opinion. The petition for writ of error is denied.
```
[Federal Register Volume 61, Number 83 (Monday, April 29, 1996)]
[Notices]
[Page 18724]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 96-10529]

-----------------------------------------------------------------------

DEPARTMENT OF DEFENSE

Defense Science Board Task Force on Image-Based Automatic Target 
Recognition

ACTION: Notice of Advisory Committee meetings.

-----------------------------------------------------------------------

SUMMARY: The Defense Science Board Task Force on Image-Based Automatic 
Target Recognition will meet in closed session on May 14-15, 1996 at 
XONTECH, Inc. Van Nuys, California.
    The mission of the Defense Science Board is to advise the Secretary 
of Defense through the Under Secretary of Defense for Acquisition and 
Technology on scientific and technical matters as they affect the 
perceived needs of the Department of Defense. At this meeting the Task 
Force will assess the ability of automatic/aided target recognition 
technology and systems to support important military missions, 
principally in the near- and mid-term. The Task Force should 
concentrate on those technologies and systems that use imagery (EO, IR 
or radar) as their primary input medium.
    In accordance with Section 10(d) of the Federal Advisory Committee 
Act, Public Law 92-463, as amended (5 U.S.C. App. II, (1988)), it has 
been determined that this DSB Task Force meeting concerns matters 
listed in 5 U.S.C. 552b(c)(1) (1988), and that accordingly this meeting 
will be closed to the public.

    Dated: April 23, 1996.
L. M. Bynum,
Alternate OSD Federal Register Liaison Officer, Department of Defense.
[FR Doc. 96-10529 Filed 4-26-96; 8:45 am]
BILLING CODE 5000-04-M
```
Exhibit 32.1

                            CERTIFICATION PURSUANT TO
                             18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

     In connection with the Quarterly Report of BioForce Nanosciences  Holdings,
Inc. (the "Company") on Form 10-QSB for the period ended June 30, 2006, as filed
with the Securities and Exchange  Commission on the date hereof (the  "Report"),
I, Eric Henderson,  Chief Executive Officer of the Company, certify, pursuant to
18 U.S.C. Sec. 1350, as adopted pursuant to Sec. 906 of the  Sarbanes-Oxley  Act
of 2002, that:

     (1) The Report fully  complies  with the  requirements  of Section 13(a) or
     15(d) of the Securities Exchange Act of 1934; and

     (2)  The  information  contained  in the  Report  fairly  presents,  in all
     material respects,  the financial condition and result of operations of the
     Company.


/s/   ERIC HENDERSON
---------------------------------
Eric Henderson
Chief Executive Officer
August 11, 2006



     A signed  original of this  written  statement  required by Section 906, or
     other document  authenticating,  acknowledging,  or otherwise  adopting the
     signature that appears in typed form within the electronic  version of this
     written  statement has been provided to the Company and will be retained by
     the Company and furnished to the Securities and Exchange  Commission or its
     staff upon  request.  The foregoing  certifications  are  accompanying  the
     Company's Form 10-QSB solely pursuant to section 906 of the  Sarbanes-Oxley
     Act of 2002  (subsections (a) and (b) of section 1350,  chapter 63 of title
     18,  United  States Code) and is not being filed as part of the Form 10-QSB
     or as a separate disclosure document.